Contego Medical’s Paladin Carotid Postdilation Balloon System Launched in Europe
January 14, 2016—Contego Medical announced the European commercialization of the Paladin carotid postdilation angioplasty balloon for patients undergoing carotid stenting procedures. The Paladin device features the company’s Integrated Embolic Protection (IEP) technology. IEP combines embolic protection and treatment into one device to aim to simplify the procedure and improve patient outcomes.
The company also advised that the Paladin system will be presented and featured in live cases on January 26 during the Technical Forum, “Deep Dive Session: Carotid Revascularization,” at LINC 2016, the Leipzig Interventional Course. LINC 2016 will convene January 26 to 29 in Leipzig, Germany.
According to Contego Medical, the Paladin system improves outcomes by reducing the risk of embolization during postdilation, when the patient has the highest risk of embolic events. The intuitive and versatile single-step system integrates a postdilation balloon proximally and an embolic protection filter at the distal catheter tip. Before postdilation, the physician deploys the adjustable 40-μm filter that provides protection against macro- and microembolic debris.
In the company’s announcement, Alberto Cremonesi, MD, commented, “The Paladin system represents a significant development in embolic protection. In a single step, I can postdilate the carotid stent and capture smaller embolic debris using the 40-μm filter. I look forward to more broadly using the intuitive system in my practice.” Dr. Cremonesi is Director of Interventional Cardio-Angiology at Villa Maria Cecilia Hospital in Cotignola, Italy.
Physicians Ravish Sachar, MD, and Jay Yadav, MD, founded Contego Medical in 2005. Dr. Sachar, who is the company’s CEO, commented in the announcement, “The European launch of the Paladin system marks a major milestone for Contego. After receiving approval in 2015, the European postmarket registry results have been very positive. We are excited to bring this treatment option to European physicians and patients.”